Barclays Lowers Pacira BioSciences (NASDAQ:PCRX) Price Target to $17.00

Pacira BioSciences (NASDAQ:PCRX) had its price target cut by Barclays from $25.00 to $17.00 in a research report report published on Tuesday,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other analysts also recently weighed in on PCRX. HC Wainwright dropped their target price on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Piper Sandler downgraded Pacira BioSciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research report on Friday, November 8th. StockNews.com cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Finally, Royal Bank of Canada lifted their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $16.60 on Tuesday. The business has a 50 day moving average of $15.75 and a 200 day moving average of $20.74. The company has a market capitalization of $766.42 million, a price-to-earnings ratio of -8.18 and a beta of 0.82. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $35.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC increased its stake in shares of Pacira BioSciences by 1,780.2% during the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after buying an additional 177,557 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after buying an additional 198,936 shares during the period. Legato Capital Management LLC increased its stake in shares of Pacira BioSciences by 74.0% during the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock valued at $1,514,000 after buying an additional 22,497 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Pacira BioSciences during the second quarter valued at approximately $2,726,000. Finally, QRG Capital Management Inc. increased its stake in shares of Pacira BioSciences by 42.0% during the first quarter. QRG Capital Management Inc. now owns 22,708 shares of the company’s stock valued at $664,000 after buying an additional 6,721 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.